Background: In multiple sclerosis (MS), the frequency of hypogammaglobulinemia is unknown. We aimed to evaluate the frequency of reduced immunoglobulin (Ig) concentrations and its association with immunotherapy and disease course in two independent MS cohorts.
Methods: In our retrospective cross-sectional study, MS patients and control patients with head or neck pain from Bern University Hospital (Bern, Switzerland) and Eginition University Hospital (Athens, Greece) were included. The lower limits of normal (LLN) for serum Ig concentration were IgG < 700 mg/dl, IgM < 40 mg/dl, and IgA < 70 mg/dl. Mann-Whitney test, analysis of variance test, and multiple linear regression analysis were employed.
Results: In total, 327 MS patients were retrospectively identified (Bern/Athens: = 226/101). Serum IgG concentrations were frequently under LLN in both MS cohorts (Bern/Athens: 15.5%/14.9%), even when considering only untreated patients (Bern/Athens: 7.9%/8.6%). MS patients ( = 327) were significantly more likely to have IgG concentrations below LLN and below 600 mg/dl in comparison with controls ( = 58) ( = 0.015 and 0.047, respectively). Between both patient groups, no significant differences were found in frequencies of IgA and IgM concentrations under LLN [ (MS patients/controls): IgA 203/30, IgM 224/24]. Independently of age, secondary progressive MS patients had lower IgG concentrations than relapsing-remitting and primary progressive patients (both: ⩽ 0.01). After adjusting for sex, age, and disease course, IgG concentrations were lower in patients treated with rituximab ( = 0.001; = 42/327), intravenous corticosteroids ( < 0.001; = 16/327), natalizumab ( < 0.001; = 48/327), and fingolimod ( = 0.003; = 6/327).
Conclusion: Our study demonstrated high prevalence rates of reduced serum IgG concentrations in MS patients with and without disease-modifying treatments. The significance of lower IgG concentrations at the levels noted is unclear considering that infections or interference with antibody production generally occur when IgG levels are much lower, at or below 400 mg/dl. However, the information is useful to monitor IgG levels especially with anti-B-cell therapies and consider IgG substitution when levels drop below 400 mg/dl.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6767745 | PMC |
http://dx.doi.org/10.1177/1756286419878340 | DOI Listing |
Alzheimers Dement
December 2024
Massachusetts General Hospital, Boston, MA, USA.
Background: Amyloid-targeting antibodies have been shown to be remarkably effective at clearing amyloid plaques from the Alzheimer's disease (AD) brain. To date, preclinical assessments have used animal models that develop only amyloid pathology, whereas AD patients present with tau pathology, neuroinflammation, and other concurrent neuropathologies. Deciphering how successful anti-amyloid therapies impact the synergistic interplay of amyloid and tau will be critical in determining which secondary disease processes can be slowed, interrupted, or reversed by amyloid-targeting immunotherapies.
View Article and Find Full Text PDFPLoS One
January 2025
Sleman Health and Demographic Surveillance System, Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada, Yogyakarta, Indonesia.
Background: This study describes the seroconversion and serodynamics of IgG antibodies against the RBD of SARS-CoV-2 in the general population of Sleman District, Yogyakarta Special Province. We aim to identify possible factors that correlate with the seroconversion and serodynamics of IgG antibodies against the RBD of SARS-CoV-2.
Methods: We performed a longitudinal study of the population at Health and Demographic Surveillance System (HDSS) Sleman, Yogyakarta, Indonesia.
Bioelectrochemistry
December 2024
Department of Chemistry, Faculty of Science, Chiang Mai University, Chiang Mai 50200, Thailand; Center of Excellence for Innovation in Chemistry, Faculty of Science, Chiang Mai University, Chiang Mai 50200, Thailand. Electronic address:
Accurate quantification of specific biomarkers is essential for clinical diagnosis and evaluating therapeutic efficacy. A self-signal-amplifying poly(acrylic acid) (PAA)/polyaniline (PANI) film-modified disposable and cost-effective screen-printed carbon electrode (SPCE) has been developed for constructing new label-free immunosensors targeting two model biomarkers: human immunoglobulin G (IgG) and alpha-fetoprotein (AFP). The electrochemically deposited PAA/PANI film on the SPCE serves a dual function: both a bio-immobilization support and a signal amplifier, enhancing biomarker detection sensitivity and efficiency.
View Article and Find Full Text PDFJ Anim Sci
January 2025
Selko USA, Indianapolis, IN 46231, USA.
Seventy-two non-lactating, pregnant Angus cows (initial body weight (BW) = 637 ± 13 kg; body condition score (BCS) = 5.5 ± 0.07 yr; and age = 6.
View Article and Find Full Text PDFMicrosyst Nanoeng
December 2024
Research Center for Bionic Sensing and Intelligence, Institute of Biomedical and Health Engineering, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, 518055, Shenzhen, China.
We present a versatile platform for label-free magnetic separation of plasma, tailored to accommodate diverse environments. This innovative device utilizes an advanced long-short alternating double Halbach magnetic array, specifically engineered for optimal magnetic separation. The array's adaptability allows for seamless integration with separation channels of varying sizes, enabling static separation of whole blood.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!